-
Roche Posts 5% H1 Sales Growth, Led by New Drugs and Immunodiagnostics
•
Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) reported a 5% year-on-year (YOY) increase in overall group sales at constant exchange rates (CER) to CHF 32.3 billion (USD 33.3 billion) for the first half of 2022. The growth was driven by new drugs for hemophilia, cancer, and neurological disorders, which…
-
InnoCare’s Tafasitamab Receives First Prescription in China’s Bo’Ao Lecheng Pilot Zone
•
China-based InnoCare (HKG: 9969) announced that the first prescription for its pipeline candidate tafasitamab (trade name: Monjuvi) has been issued in the Bo’Ao Lecheng Medical Tourism Pilot Zone. The drug is intended for the treatment of relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) in patients not eligible for…
-
Harbin Gloria Partners with Genolmmune on PD-1 and Neoantigen Therapy for NSCLC
•
China-based Harbin Gloria Pharmaceuticals Co., Ltd (SHE: 002437) has partnered with Genolmmune Therapeutics Biotechnology Co., Ltd, a BGI Genomics subsidiary focused on tumor immune cell therapy. The collaboration aims to develop Gloria’s PD-1 monoclonal antibody zimberelimab in combination with Genolmmune’s injectable Neo-T neoantigen immunotherapy for non-small cell lung cancer (NSCLC).…
-
MAXVAX Biotech Raises RMB500M in Series B to Advance Vaccine Pipelines
•
MAXVAX Biotechnology LLC, a Chengdu-based vaccine and novel adjuvant developer, reportedly raised RMB500 million ($73.9 million) in a Series B financing round. The funding was led by China Life Equity Investment and included participation from existing investors Sherpa Healthcare Partners and GL Ventures, as well as new investors Shizhen Capital…
-
Livzon’s V-01 and V-01D-351 Vaccines Show Strong Safety, Immunity as COVID Boosters
•
China-based Livzon Pharmaceutical Group (HKG: 1513) released clinical data for its recombinant novel coronavirus fusion protein vaccine V-01 and bivalent vaccine V-01D-351, showing strong safety and immunogenicity as sequential booster shots. The vaccines are co-developed by Livzon subsidiary Zhuhai Livzon Monoclonal Antibodies Biotechnology and the Chinese Academy of Sciences’ Institute…
-
CANbridge Pharmaceuticals Doses First Patient in CAN103 Gaucher Disease Trial
•
China-based rare disease firm CANbridge Pharmaceuticals announced the dosing of the first patient in a Phase I/II clinical trial for CAN103, its enzyme replacement therapy (ERT) candidate, in treatment-naïve patients with type I and III Gaucher disease. The trial marks progress in CANbridge’s partnership with WuXi Biologics (HKG: 2269) to…
-
InxMed Receives $10M Debt Financing from SPD Silicon Valley Bank to Advance FAK Inhibitor IN10018
•
China-based biotech firm InxMed (Nanjing) Co., Ltd announced it has received $10 million in debt financing from SPD Silicon Valley Bank. The funding will support the development of IN10018 (BI853520), a focal adhesion kinase (FAK) inhibitor licensed from iPharma Ltd and Boehringer Ingelheim. Drug ProfileIN10018 is under clinical investigation in…
-
Frontera Therapeutics Raises $160M in Series B to Advance Gene Therapy FT-001
•
Sino-US gene therapy specialist Frontera Therapeutics has closed a $160 million Series B funding round, bringing total investments in the firm to $195 million. The round follows a $35 million Series A led by OrbiMed and Creacion Ventures. Investors in the latest round include Boyu Capital, Sequoia China, OrbiMed, and…
-
DAC Biotech’s DXC005 ADC Doses First Patient in Beijing Cancer Hospital Trial
•
China-based Hangzhou DAC Biotech Co., Ltd announced the first patient enrollment and dosing of its antibody drug conjugate (ADC) DXC005 in a clinical study at Beijing Cancer Hospital’s gastrointestinal oncology department. The trial marks progress in DAC Bio’s pipeline of oncology-focused ADC candidates. Drug ProfileDXC005 combines a MUC-1 targeting antibody…
-
J&J Q2 Sales Rise 8% but Profits Plunge 23% Amid China COVID Lockdowns
•
US giant Johnson & Johnson (J&J, NYSE: JNJ) reported Q2 2022 financials, showing 8.0% year-on-year (YOY) sales growth in constant currency to $24.02 billion but a 23.3% net profit drop to $4.81 billion. CFO Joseph Wolk cited the strong dollar and China’s COVID-19 lockdowns as key factors, prompting a full-year…
-
Novartis Q2 Results Show 5% Growth, Led by Entresto and Cosentyx
•
Swiss pharma giant Novartis (NYSE: NVS) reported a 5% year-on-year (YOY) revenue increase in constant currency terms to $12.79 billion in Q2 2022, though dollar sales dipped 1% due to currency strength. Earnings per share (EPS) rose 1%, or 10% excluding the $20.7 billion Roche stake sale in November 2021.…
-
Aidea Pharmaceutical Acquires 19.96% ND Pharm Stake to Boost Urokinase Business
•
China’s Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has acquired a 19.96% stake in ND Pharm, becoming the firm’s second-largest shareholder. Financial terms were undisclosed. The move positions Aidea to leverage ND Pharm’s market-leading urokinase products, complementing its existing human protein portfolio. ND Pharm’s Market PositionND Pharm markets injectable urokinase…
-
NHSA Issues New Medical Service Pricing Policy to Enhance Public Welfare and Innovation
•
The National Healthcare Security Administration (NHSA) has released a new notification on medical service pricing management, effective immediately. The policy aims to stabilize and orderly manage medical service pricing, enhance public welfare in basic medical services, promote innovation, and ensure high-quality, efficient, and affordable healthcare for the public. Key Policies…
-
MicroPort CardioFlow Completes First Clinical Use of Dry Valve Transcatheter Mitral Valve System
•
MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off of China-based MicroPort Scientific Corp (HKG: 0853), announced the successful completion of the first clinical application of its transcatheter mitral valve replacement (TMVR) system. The procedure demonstrated the system’s safety and efficacy, with postoperative mitral regurgitation resolved and no complications such…
-
WuXi Biologics to Build $1.4B CRDMO Hub in Singapore, Creating 1,500 Jobs
•
China-based WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO), announced plans to establish a $1.4 billion CRDMO service center in Singapore. The facility, supported by Singapore’s Economic Development Board (EDB), will include a biologic drug R&D service center and large-scale production plant, adding 120,000 liters…
-
Antengene and Celularity Partner on Bispecific Antibody and NK Cell Therapy Combo
•
China-based Antengene Corporation Ltd (HKG: 6996) announced a preclinical partnership with U.S. firm Celularity Inc. to evaluate the combined potential of Antengene’s bispecific antibody (BsAb) and Celularity’s cryopreserved natural killer (NK) cell therapy derived from human placental hematopoietic stem cells. Financial terms were not disclosed. Collaboration DetailsThe partnership aims to…
-
Kexing Pharmaceutical Launches Phase III Influenza Vaccine Study in Chile
•
China-based Kexing Pharmaceutical (SHA: 688136) announced the start of a Phase III clinical trial in Chile to evaluate the safety and immunogenicity of its quadrivalent influenza virus split vaccine in individuals aged three and older. The vaccine received market approval in China in June 2020. Study DetailsThe trial will enroll…
-
Henlius Biotech’s HLX14 Biosimilar Wins TGA Approval for Global Phase III Osteoporosis Study
•
China-based Shanghai Henlius Biotech Inc. (HKG: 2696) received approval from Australia’s Therapeutic Goods Administration (TGA) to conduct a global multi-center Phase III study of HLX14, its biosimilar of Amgen’s Prolia/Xgeva (denosumab), targeting postmenopausal osteoporosis in high-fracture-risk women. Study DetailsThe trial will evaluate the efficacy, safety, tolerability, and immunogenicity of HLX14…
-
Luye Pharma’s Rotigotine Microspheres Meet Phase III Goals in Parkinson’s Study
•
China-based Luye Pharma Group (HKG: 2186) announced that its Phase III clinical study for rotigotine extended-release microspheres for injection (LY03003) in Parkinson’s disease (PD) met all pre-set endpoints. The trial demonstrated the drug’s efficacy and safety in early-stage PD patients. Study DetailsThe multi-center, randomized, double-blind, placebo-controlled study enrolled 294 early…
-
Eli Lilly’s Retevmo Wins Special Approval in China’s Lecheng Medical Pilot Zone
•
Eli Lilly & Co. (NYSE: LLY) has secured special approval for its RET kinase inhibitor Retevmo (selpercatinib) in China’s Bo’Ao Lecheng Medical Tourism Pilot Zone. The drug will be available at the Boao Super Hospital to treat RET gene fusion-positive non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC), and…
